Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 663 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2013  |  Volume : 17  |  Issue : 8  |  Page : 453-457

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Eastern Saudi Arabia cohort of the A 1 chieve study

1 Department of Internal Medicine, Endocrinology, Mana General Hospital, Jubail, Saudi Arabia
2 Department of Internal Medicine, Endocrinology, Mana General Hospital, Khobar, Saudi Arabia
3 Department of Endocrinology, Saad Specialist Hospital, Khobar, Saudi Arabia

Correspondence Address:
Faisal Hashim
Mana General Hospital, Jubail
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.122074

Rights and Permissions

Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Eastern Saudi Arabia. Results: A total of 1040 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (n = 489), insulin detemir (n = 360), insulin aspart (n = 37), basal insulin plus insulin aspart (n = 96) and other insulin combinations (n = 57). At baseline glycaemic control was poor for both insulin naïve (mean HbA 1 c: 10.0%) and insulin user (mean HbA 1 c: 9.2%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA 1 c (insulin naïve: −2.7%, insulin users: −1.7%). No major hypoglycaemic episodes were observed at 24 weeks. SADR was reported in 0.6% of insulin users. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded207    
    Comments [Add]    

Recommend this journal